ALX-803-335-C100
antibody from Enzo Life Sciences
Targeting: BIRC2
API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48
Antibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Immunocytochemistry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-803-335-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-803-335-C100, RRID:AB_2051135
- Product name
- c-IAP1 monoclonal antibody (1E1-1-10)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse
- Host
- Rat
- Isotype
- IgG
- Antibody clone number
- 1E1-1-10
- Vial size
- 100 μg
- Storage
- -80°C
- Handling
- Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80¡C.
Submitted references Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling.
Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination.
An inactivating caspase 11 passenger mutation originating from the 129 murine strain in mice targeted for c-IAP1.
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2.
Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding.
TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.
Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.
TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.
A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.
Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance.
Kocab AJ, Veloso A, Paulsen MT, Ljungman M, Duckett CS
Oncogene 2015 Oct;34(43):5472-81
Oncogene 2015 Oct;34(43):5472-81
Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination.
de Almagro MC, Goncharov T, Newton K, Vucic D
Cell death & disease 2015 Jun 25;6:e1800
Cell death & disease 2015 Jun 25;6:e1800
An inactivating caspase 11 passenger mutation originating from the 129 murine strain in mice targeted for c-IAP1.
Kenneth NS, Younger JM, Hughes ED, Marcotte D, Barker PA, Saunders TL, Duckett CS
The Biochemical journal 2012 Apr 15;443(2):355-9
The Biochemical journal 2012 Apr 15;443(2):355-9
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2.
Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, Meier P
Cell death and differentiation 2011 Aug;18(8):1376-86
Cell death and differentiation 2011 Aug;18(8):1376-86
Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding.
Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H, Day CL, Vaux DL, Silke J
The Journal of biological chemistry 2010 Jun 4;285(23):17525-36
The Journal of biological chemistry 2010 Jun 4;285(23):17525-36
TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.
Lluis JM, Nachbur U, Cook WD, Gentle IE, Moujalled D, Moulin M, Wong WW, Khan N, Chau D, Callus BA, Vince JE, Silke J, Vaux DL
PloS one 2010 Jan 8;5(1):e8620
PloS one 2010 Jan 8;5(1):e8620
Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.
Geserick P, Hupe M, Moulin M, Wong WW, Feoktistova M, Kellert B, Gollnick H, Silke J, Leverkus M
The Journal of cell biology 2009 Dec 28;187(7):1037-54
The Journal of cell biology 2009 Dec 28;187(7):1037-54
TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.
Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, Davidson AJ, Callus BA, Wong WW, Gentle IE, Carter H, Lee EF, Walczak H, Day CL, Vaux DL, Silke J
The Journal of biological chemistry 2009 Dec 18;284(51):35906-15
The Journal of biological chemistry 2009 Dec 18;284(51):35906-15
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.
Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J
The Journal of cell biology 2008 Jul 14;182(1):171-84
The Journal of cell biology 2008 Jul 14;182(1):171-84
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J
Cell 2007 Nov 16;131(4):682-93
Cell 2007 Nov 16;131(4):682-93
A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.
Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, Sage D, Slisz J, Tran M, Straub C, Ramsey T, Iourgenko V, Huang A, Chen Y, Schlegel R, Labow M, Fawell S, Sellers WR, Zawel L
Cancer research 2007 Dec 15;67(24):11493-8
Cancer research 2007 Dec 15;67(24):11493-8
Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance.
Silke J, Kratina T, Chu D, Ekert PG, Day CL, Pakusch M, Huang DC, Vaux DL
Proceedings of the National Academy of Sciences of the United States of America 2005 Nov 8;102(45):16182-7
Proceedings of the National Academy of Sciences of the United States of America 2005 Nov 8;102(45):16182-7
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Western blot analysis of c-IAP1 in mouse bone marrow-derived macrophages of the indicated strains lysed in DISC buffer (150mM sodium chloride, 2mM EDTA, 1% Triton X-100, 10% glycerol, 20mM Tris pH 7.5) using MAb to c-IAP1 (1E1-1-10) (Prod. No. ALX-803-335) followed by HRP-anti rat antibody and developed by ECL.Molecular weight marker (kD) is shown at the left. Lanes have been digitally excised from a single blot to aid comparison.
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Western blot analysis of human c-IAP1 using MAb to c-IAP1 (1E1-1-10)A: MDA-MB-231 cell lysateB: MDA-MB-231 +LBW 1µM/1h cell lysate (LBW causes degradation of c-IAP1; A. Gaither, et al., 2007)(Image courtesy ofÊDr. Pascal Meier, The Institute of Cancer Research, London.)
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- MAb to c-IAP1 (1E1-1-10) is specific for mouse and human c-IAP1. A) Wild type and c-IAP1-/- MEFs were treated +/- TWEAK for 6 hours and whole cell lysates prepared and separated on an SDS-PAGE gel, transferred to a PVDF membrane and probed with MAb to c-IAP1 (1E1-1-10).ÊTWEAK causes a partial loss of c-IAP1. B) 4 human cell lines were treated overnight with an IAP antagonist that induces rapid degradation of c-IAP1. Cells were lysed with DISC lysis buffer and separated on an SDS-PAGE gel, transferred and probed with the MAb to c-IAP1 (1E1-1-10) as in A. XIAP and c-IAP2 blots demonstrate the specificity of the c-IAP1 antibody.